论文信息 - What is the best way to manage patients treated with gefitinib for non-small-cell lung cancer? - 字舞流文

What is the best way to manage patients treated with gefitinib for non-small-cell lung cancer?

R. Herbst | A. Onn

[1] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[2] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[3] M. Kris,et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4] N. Thatcher,et al. Pr4 ISEL: A Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens , 2005 .

[5] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[6] Mark R. Green,et al. Targeting targeted therapy. , 2004, The New England journal of medicine.